ABEONA THERAPEUTICS INC. Proceeds from Stock Options Exercised
ABEONA THERAPEUTICS INC. (ABEO) reported Proceeds from Stock Options Exercised of $831.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2022-11-14
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for the quarter ending 2021-09-30 was $140.00K.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for the quarter ending 2021-06-30 was $24.00K.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for the quarter ending 2021-03-31 was $667.00K.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for fiscal 2021 was $831.00K, a 369.49% increase from fiscal 2020.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for fiscal 2020 was $177.00K, a 81.73% decline from fiscal 2019.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for fiscal 2019 was $969.00K, a 56.82% decline from fiscal 2018.
- ABEONA THERAPEUTICS INC. proceeds from stock options exercised for fiscal 2018 was $2.24M, a 552.33% increase from fiscal 2017.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 3 month as first filed | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $140.00K derived: sum of 2 quarters · filed 2022-11-14 | $164.00K derived: sum of 3 quarters · filed 2022-11-14 | $831.00K 10-K · filed 2022-03-31 | |
| 2021-09-30 | $140.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $164.00K derived: sum of 2 quarters · filed 2022-11-14 | $831.00K 10-Q · filed 2022-11-14 | $833.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $691.00K 10-Q · filed 2022-08-11 | $693.00K derived: sum of 3 quarters · filed 2022-08-11 | $693.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $667.00K 10-Q · filed 2022-05-13 | $669.00K derived: sum of 2 quarters · filed 2022-05-13 | $669.00K derived: sum of 3 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.00K derived: sum of 2 quarters · filed 2022-03-31 | $177.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $175.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $175.00K 10-Q · filed 2021-07-28 | ||||
| 2019-12-31 | $556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $556.00K derived: sum of 2 quarters · filed 2021-03-24 | $941.00K derived: sum of 3 quarters · filed 2021-03-24 | $969.00K 10-K · filed 2021-03-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $385.00K derived: sum of 2 quarters · filed 2020-11-09 | $413.00K 10-Q · filed 2020-11-09 | $412.00K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $385.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $413.00K 10-Q · filed 2020-08-10 | $412.00K derived: sum of 3 quarters · filed 2020-08-10 | $491.00K derived: sum of 4 quarters · filed 2020-08-10 | |
| 2019-03-31 | $28.00K 10-Q · filed 2020-05-06 | $27.00K derived: sum of 2 quarters · filed 2020-05-06 | $106.00K derived: sum of 3 quarters · filed 2020-05-06 | $587.00K derived: sum of 4 quarters · filed 2020-05-06 | |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $78.00K derived: sum of 2 quarters · filed 2020-03-16 | $559.00K derived: sum of 3 quarters · filed 2020-03-16 | $2.24M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $560.00K derived: sum of 2 quarters · filed 2019-11-12 | $2.25M 10-Q · filed 2019-11-12 | $2.50M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-06-30 | $481.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $2.17M 10-Q · filed 2019-08-09 | $2.42M derived: sum of 3 quarters · filed 2020-03-16 | $2.42M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2018-03-31 | $1.69M 10-Q · filed 2019-05-10 | $1.94M derived: sum of 2 quarters · filed 2020-03-16 | $1.94M derived: sum of 3 quarters · filed 2020-03-16 | $2.03M derived: sum of 4 quarters · filed 2020-03-16 | |
| 2017-12-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $259.00K derived: sum of 2 quarters · filed 2020-03-16 | $344.00K derived: sum of 3 quarters · filed 2020-03-16 | $344.00K 10-K · filed 2020-03-16 | |
| 2017-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $93.00K derived: sum of 2 quarters · filed 2018-11-09 | $93.00K 10-Q · filed 2018-11-09 | $443.00K derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $85.00K 10-Q · filed 2018-08-09 | $435.00K derived: sum of 3 quarters · filed 2019-03-18 | $435.00K derived: sum of 4 quarters · filed 2019-03-18 | |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-10 | $1.00K 10-Q · filed 2017-05-15 | $350.00K derived: sum of 2 quarters · filed 2019-03-18 | $350.00K derived: sum of 3 quarters · filed 2019-03-18 | $350.00K derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $350.00K derived: sum of 2 quarters · filed 2019-03-18 | $350.00K derived: sum of 3 quarters · filed 2019-03-18 | $350.00K 10-K · filed 2019-03-18 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-15 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-30 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $0.00 derived: sum of 2 quarters · filed 2015-03-31 | $0.00 10-K · filed 2015-03-31 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $0.00 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-14 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | $18.00K derived: sum of 2 quarters · filed 2015-03-31 | $29.00K 10-K · filed 2015-03-31 | ||
| 2013-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | $29.00K 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | $11.00K 10-Q · filed 2014-08-14 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $0.00 derived: sum of 2 quarters · filed 2014-03-26 | $0.00 10-K · filed 2014-03-26 | ||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $0.00 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | $0.00 10-Q · filed 2013-08-14 | ||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | $0.00 derived: sum of 2 quarters · filed 2012-03-23 | $0.00 10-K · filed 2012-03-23 | ||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | |||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-15 | ||||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | $52.00K derived: sum of 2 quarters · filed 2012-03-23 | $192.00K 10-K · filed 2012-03-23 | ||
| 2010-09-30 | $52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $192.00K 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | $140.00K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |